Jennifer Kannookaden
Mount Prospect, ILNPI 1497401863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.
Across 214 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$514
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$512
- AbbVie$505
- Axsome Therapeutics, Inc.$473
- Otsuka America Pharmaceutical, Inc.$422
- Johnson & Johnson$404
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 26 | $514 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $512 |
| AbbVie | 24 | $505 |
| Axsome Therapeutics, Inc. | 18 | $473 |
| Otsuka America Pharmaceutical, Inc. | 24 | $422 |
| Johnson & Johnson | 16 | $404 |
| Corium, LLC | 17 | $357 |
| Tris Pharma Inc | 16 | $256 |
| E.r. Squibb & Sons, L.L.C. | 9 | $203 |
| Alkermes, Inc. | 8 | $160 |
| Indivior Inc. | 5 | $132 |
| Teva Pharmaceuticals USA, Inc. | 4 | $89 |
| Noven Therapeutics, LLC | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $72 |
| Neurocrine Biosciences, Inc. | 3 | $72 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Collegium Pharmaceutical, Inc. | 2 | $47 |
| Orexo US, Inc. | 2 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Almatica Pharma LLC | 1 | $25 |
| Biogen | 1 | $24 |
| Neos Therapeutics, LP | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 11 | $105,804 |
| VraylarCariprazine Hcl | 37 | $56,007 |
| PerserisRisperidone | 11 | $23,566 |
| RexultiBrexpiprazole | 14 | $19,930 |
| Lurasidone Hcl | 20 | $11,671 |
| Aripiprazole | 106 | $6,057 |
| Asenapine Maleate | 14 | $2,706 |
| Bupropion XlBupropion Hcl | 118 | $2,624 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 81 | $2,495 |
| Trazodone Hcl | 197 | $2,417 |
| Hydroxyzine Hcl | 65 | $1,732 |
| Duloxetine Hcl | 165 | $1,708 |
| Escitalopram Oxalate | 158 | $1,621 |
| Olanzapine | 60 | $1,578 |
| Quetiapine Fumarate | 72 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $89 | $105,80411 claims |
| AbbVieVraylar | $505 | $56,00737 claims |
| Indivior Inc.Perseris | $132 | $23,56611 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $422 | $19,93014 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $809112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Illinoison file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.